Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei and Appendix Tumours

被引：15
作者：
Lansom J. [1 ,2 ]
Alzahrani N. [1 ,2 ]
Liauw W. [2 ,3 ]
Morris D.L. [1 ,2 ]
机构：
[1] Department of Surgery, University of New South Wales, Sydney, NSW
[2] Department of Surgical Oncology, St George Hospital, Sydney, NSW
[3] Cancer Care Centre, St George Hospital, Sydney, NSW
来源：
Indian Journal of Surgical Oncology | 2016年 / 7卷 / 2期
关键词：
Appendiceal neoplasms; Cytoreductive surgery; HIPEC; Hyperthermic intraperitoneal chemotherapy; Mucocoele; Peritoneal surface malignancy; Peritonectomy; PMP; Pseudomyxoma peritonei; Surgery; Surgical oncology;
D O I：
10.1007/s13193-015-0478-9
中图分类号：
学科分类号：
摘要：
Pseudomyxoma peritonei (PMP) is the intra-peritoneal accumulation of mucus due to mucinous neoplasia, most often from a ruptured mucinous appendiceal neoplasm. A similar syndrome is caused by appendix cancer and other gastrointestinal malignancies. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) provides long-term survival in selected patients with these conditions. The management of the appendiceal neoplasm prior to development of peritoneal involvement is initially discussed. This is followed by an overview of the management of peritoneal disease caused by appendiceal neoplasms. The principles and basic techniques of CRS and intraperitoneal chemotherapy (both intraoperative and post operative) are then discussed. Survival outcomes from several large studies are summarised. Prognostic factors are also discussed. We report our basic outcome data for the 345 patients with PMP or appendix cancer treated at our institution. Finally, the promising upcoming treatment of mucolytic therapy is discussed. We conclude that appendiceal neoplasms, although rare can cause significant morbidity and mortality. With optimal management long-term survival is possible in the majority of patients. The key to treatment is complete cytoreduction and use of hyperthermic intraperitoneal chemotherapy. © 2015, Indian Association of Surgical Oncology.
引用
收藏
页码：166 / 176
页数：10
相关论文
共 72 条
  • [51] Gonzalez-Moreno S., Gonzalez-Bayon L.A., Ortega-Perez G., Hyperthermic intraperitoneal chemotherapy: rationale and technique, World J Gastrointest Oncol, 2, pp. 68-75, (2010)
  • [52] van Ruth S., Verwaal V.J., Hart A.A., van Slooten G.W., Zoetmulder F.A., Heat penetration in locally applied hyperthermia in the abdomen during intra-operative hyperthermic intraperitoneal chemotherapy, Anticancer Res, 23, pp. 1501-1508, (2003)
  • [53] Fujimoto S., Takahashi M., Kobayashi K., Et al., Cytohistologic assessment of antitumor effects of intraperitoneal hyperthermic perfusion with mitomycin c for patients with gastric cancer with peritoneal metastasis, Cancer, 70, pp. 2754-2760, (1992)
  • [54] Witkamp A.J., de Bree E., Kaag M.M., van Slooten G.W., van Coevorden F., Zoetmulder F.A., Extensive surgical cytoreduction and intraoperative hyperthermic intraperitoneal chemotherapy in patients with pseudomyxoma peritonei, Bri J Surg, 88, pp. 458-463, (2001)
  • [55] Clavien P.A., Barkun J., de Oliveira M.L., Et al., The clavien-dindo classification of surgical complications: five-year experience, Ann Surg, 250, pp. 187-196, (2009)
  • [56] Dindo D., Demartines N., Clavien P.A., Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey, Ann Surg, 240, pp. 205-213, (2004)
  • [57] Chua T.C., Yan T.D., Saxena A., Morris D.L., Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure? a systematic review of morbidity and mortality, Ann Surg, 249, pp. 900-907, (2009)
  • [58] Yang T.X., Morris D.L., Chua T.C., Pelvic exenteration for rectal cancer: a systematic review, Dis Colon Rectum, 56, pp. 519-531, (2013)
  • [59] Sugarbaker P.H., Alderman R., Edwards G., Et al., Prospective morbidity and mortality assessment of cytoreductive surgery plus perioperative intraperitoneal chemotherapy to treat peritoneal dissemination of appendiceal mucinous malignancy, Ann Surg Oncol, 13, pp. 635-644, (2006)
  • [60] Chua T.C., Moran B.J., Sugarbaker P.H., Et al., Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy, J Clin Oncol, 30, pp. 2449-2456, (2012)
12345678